DekaBank Deutsche Girozentrale Has $1.39 Million Position in Catalent, Inc. (NYSE:CTLT)

DekaBank Deutsche Girozentrale reduced its stake in shares of Catalent, Inc. (NYSE:CTLT) by 24.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 30,713 shares of the company’s stock after selling 9,737 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Catalent were worth $1,393,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. KB Financial Partners LLC acquired a new position in shares of Catalent during the 1st quarter worth about $30,000. Covestor Ltd grew its position in shares of Catalent by 84.9% in the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after purchasing an additional 258 shares during the period. Gladius Capital Management LP acquired a new position in shares of Catalent in the 3rd quarter valued at approximately $28,000. Exchange Traded Concepts LLC acquired a new position in shares of Catalent in the 3rd quarter valued at approximately $31,000. Finally, Cary Street Partners Investment Advisory LLC grew its position in shares of Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares during the period.

Catalent Trading Down 1.1 %

Shares of Catalent stock opened at $56.30 on Monday. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $64.46. The stock has a market cap of $10.18 billion, a P/E ratio of -8.28, a P/E/G ratio of 6.07 and a beta of 1.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The business’s 50 day moving average is $56.99 and its 200-day moving average is $47.91.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the company earned $0.62 EPS. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. Equities research analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on CTLT shares. Barclays boosted their price objective on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. StockNews.com started coverage on Catalent in a research report on Thursday. They issued a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Finally, UBS Group restated a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Catalent currently has an average rating of “Hold” and an average target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.